DID you Know :


  • That many countries in the Africa/South America/ Asia/ E.Europe have drug prices in excess of what one could get for the same product in Europe or North America.

  • That the time & development cost to obtain product registration in many Emerging markets are less than half of the time taken in Europe or North America.

  • The incremental sale revenue from Emerging Markets offer a great leverage to offset your development cost and continue building your product pipe line.

  • That a few small countries in the Emerging Markets have per capita Health Care expenditure at levels similar to developed countries.

  • That it is possible to sell your products in the Emerging Markets, without having to set up your own subsidiary and invest in marketing and infrastructure set up.

  • That Emerging Markets are growing at a pace greater than the developed countries.

  • If you look at the balance sheet of large generic companies [Regional, European, S American, Asian], you will observe that most of them make a bulk of their net profit in the Emerging markets. Most of them while active in developed markets,[ funding for which came as a result of their foray in Emerging markets for the past decade], still continue to make their money in the Emerging markets.

VALUGEN HAS BEEN ESTABLISHED WITH THE OBJECTIVE OF LEVERAGING IT’S EXPERTISE IN MORE THAN 50 COUNTRIES IN THE EMERGING AND REGULATED MARKETS TO COMPANIES WHO ARE KEEN TO START OR BUILD THEIR EXISTING OPERATIONS.